For research use only. Not for therapeutic Use.
PKCβ inhibitor 1（Cat No.:I016271） is a highly potent and selective inhibitor of protein kinase C beta (PKCβ) with significant ATP-competitive activity. It exhibits IC50 values of 21 nM and 5 nM for human PKCβ1 and PKCβ2, respectively. Compared to other PKC isozymes such as PKCα, PKCγ, and PKCε, PKCβ inhibitor 1 demonstrates more than 60-fold selectivity. This selective inhibition of PKCβ isoforms makes it a valuable tool in studying PKCβ-mediated signaling pathways and may have potential therapeutic applications in diseases where PKCβ is involved.
| Catalog Number | I016271 |
| CAS Number | 257879-35-9 |
| Molecular Formula | C₂₄H₂₁N₅O₂ |
| Purity | ≥95% |
| Target | PKC; Apoptosis |
| IUPAC Name | 3-anilino-4-[1-(3-imidazol-1-ylpropyl)indol-3-yl]pyrrole-2,5-dione |
| InChI | InChI=1S/C24H21N5O2/c30-23-21(22(24(31)27-23)26-17-7-2-1-3-8-17)19-15-29(20-10-5-4-9-18(19)20)13-6-12-28-14-11-25-16-28/h1-5,7-11,14-16H,6,12-13H2,(H2,26,27,30,31) |
| InChIKey | KIWODJBCHRADND-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)NC2=C(C(=O)NC2=O)C3=CN(C4=CC=CC=C43)CCCN5C=CN=C5 |
| Reference | [1]. Tanaka M, et al. Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.<br>[2]. Saba NS, et al. Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cells. J Investig Med. 2012 Jan;60(1):29-38. |
